Table 3.

comparison of the published phase II studies using gemcitabine and carboplatin combination as first-line chemotherapy in advanced TCC patients

Study	N	RR (%)	TTP/PFS*(mo)	OS(mo)	Neutrop-enia G3/4%	Anemia G3/4%	Thromboc-ytopenia G3/4%	CrCl < 60 or < 50* (%)	Median Age(y)	PS ≥ 2, ≤ 70%* (%)	visceral mets (%)
Carles15	17	56.3	NR	10	24	18	18	100	69	41*	29
Shannon16	17	58.8	4.6	10.5	70	18	47	77	69	29	59
Bellmunt17	16	44	NR	NR	56	50	63	100	68	13	31
Hoschke18	23	60.8	7.8	15.4	26*	30	48	52	68	21	43
Nogue-Aliguer19	41	56.1	7.2*	10.1	63	54	32	54	66	37*	20
Linardou20	56	36	4.8	7.2	28	18	17	68*	75	46	39
Olivares21	50	56	11*	11.3	42	18	20	NR	69	18*	18
Bamias22	60	38.3	7.6	16.3	52	18	23	22*	69	13	52
this study	41	46.2	7.5*	13.6	37	27	24	20	67	15	27

NR, Not reported